Medicare GLP-1 Bridge Program: Access and Implications for Beneficiaries
Starting in July 2026, Medicare will introduce the Medicare GLP-1 Bridge—a temporary program granting some beneficiaries access to GLP-1 medications via a fixed monthly fee. Running through the end of 2027, this initiative by the Centers for Medicare and Medicaid Services (CMS) aims to assess the feasibility of offering these medications to Medicare recipients who seek weight management solutions.
The program enables eligible Medicare Part D enrollees to receive GLP-1 medications for a set monthly copay of $50. Although these medications generally treat conditions like diabetes and heart issues, this program primarily targets weight management. It is crucial for those beneficiaries without a medically coverable indication under current Part D rules, as federal law limits Medicare coverage for weight loss medications.
Organizations such as the Obesity Care Advocacy Network (OCAN) have expressed strong support, calling it a significant step against the obesity epidemic. Nevertheless, some regulatory experts have raised concerns regarding program administration and costs. Bob Herman from Stat News highlighted that questions about the program's expenses remain unanswered by CMS.
CMS states that enrollees only need a prescription from their healthcare provider to participate; a prior authorization request is required for medications such as Wegovy, Zepbound, or Foundayo. Any changes in medication during the program will need new authorization, ensuring strict regulatory compliance.
The Bridge program processes prescriptions through a central processor, Bridge PCN. If it's a patient's first GLP-1 prescription under the program, the claim will be initially rejected, pending a provider-completed authorization form. Eligible participants must be enrolled in a standalone prescription drug plan or a Medicare Advantage plan, with specific criteria for those in Special Needs Plans and other programs.
To join, individuals must be over 18, with specific BMI requirements and health conditions, ranging from prediabetes to chronic kidney disease. Despite its potential, the program does not fit within traditional Medicare guidelines for weight loss medication coverage, raising concerns about compliance and potential misuse according to Christopher J. Frisina, regulatory counsel at Alston & Bird.
As the Medicare GLP-1 Bridge rolls out, CMS has yet to disclose the program’s financial implications. It operates independently from the usual Medicare Part D cost-sharing and payment structure, leaving its impact on Medicare spending to be determined.